{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:02:54Z","timestamp":1772146974308,"version":"3.50.1"},"reference-count":82,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/14712598.2023.2294001","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T10:57:05Z","timestamp":1702119425000},"page":"1265-1275","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Adjuvant immunotherapy for locally advanced renal cell carcinoma"],"prefix":"10.1080","volume":"23","author":[{"given":"Michail","family":"Alevizakos","sequence":"first","affiliation":[{"name":"Department of Hematology\/Medical Oncology, Riverside Cancer Specialists of Tidewater, Chesapeake, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"McDermott","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Division, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.03.006"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.104"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.01.005"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01090"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66077-6"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15981"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.425"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.005"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.014"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15590-6"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15625-0"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0784-6"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.738"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.4419"},{"key":"e_1_3_4_18_1","unstructured":"National Cancer Institute. Clinical Trials Using Lutetium Lu-177 Girentuximab [Internet]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/intervention\/lutetium-lu-177-girentuximab?redirect=true."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.2445"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_280817"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2298-3"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00978"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603993"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.05.004"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00479"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00559-6"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0076"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.09.008"},{"key":"e_1_3_4_29_1","unstructured":"Food and Drug Administration. FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma [Internet]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sunitinib-malate-adjuvant-treatment-renal-cell-carcinoma."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611406"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01800"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.08.011"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6994"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.5324"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.029"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4502"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy454"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S98687"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA4500"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.106"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00487-9"},{"key":"e_1_3_4_43_1","unstructured":"Food and Drug Administration. FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma [Internet]. [cited 2023 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01658-0"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02574-0"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4506"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.072"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/35025220"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0369"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz056"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.5981"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2646"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0892-6"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2023.01.011"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2020.12.005"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S360441"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02363"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz039"},{"key":"e_1_3_4_60_1","unstructured":"Food and Drug Administration. FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma [Internet]. [cited 2023 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-ipilimumab-combination-intermediate-or-poor-risk-advanced-renal-cell."},{"key":"e_1_3_4_61_1","unstructured":"Food and Drug Administration. FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma [Internet]. [cited 2023 Apr 6]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma."},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390038"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30196-6"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02684-8"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0030-x"},{"issue":"5","key":"e_1_3_4_66_1","first-page":"1","article-title":"Cancer control in low- and middle-income countries: is it time to consider screening?","volume":"5","author":"Shah SC","year":"2019","unstructured":"Shah SC, Kayamba V, Peek RM Jr, et al. Cancer control in low- and middle-income countries: is it time to consider screening? J Glob Oncol Internet. 2019;5(5):1\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/30908147","journal-title":"J Glob Oncol"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106482"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4509"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4602"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1100"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.09.001"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14282"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1576"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0051"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w"},{"key":"e_1_3_4_77_1","unstructured":"Merck. Pembrolizumab Cost Info [Internet]. [cited 2023 Jun 6]. Available from: https:\/\/www.keytruda.com\/financial-support\/."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.6592"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.016"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.35123"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2021.12.006"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0025"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071945"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2063"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2023.2294001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T19:32:01Z","timestamp":1727206321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2023.2294001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":82,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/14712598.2023.2294001"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2023.2294001","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}